Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons
Clinical Infectious Diseases · 14.06.2024 · 78 (6) · 1732-1744
DOI: 10.1093/cid/ciae010 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 22.01.2024. Verfasst von Michael G Ison und 20 weiteren Autor:innen. Beteiligte Einrichtung: Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus, Human, Viral Fusion Proteins. Die Arbeit wurde bisher 181-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals SA.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
The adjuvanted RSV prefusion F protein–based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-years-olds over 1 RSV season. We evaluated efficacy and safety of 1 RSVPreF3 OA dose and of 2 RSVPreF3 OA doses given 1 year apart against RSV-LRTD over 2 RSV seasons post–dose 1.
Methods
In this phase 3, blinded trial, ≥60-year-olds were randomized (1:1) to receive RSVPreF3 OA or placebo pre–season 1. RSVPreF3 OA recipients were re-randomized (1:1) to receive a second RSVPreF3 OA dose (RSV_revaccination group) or placebo (RSV_1dose group) pre–season 2; participants who received placebo pre–season 1 received placebo pre–season 2 (placebo group). Efficacy of both vaccine regimens against RSV-LRTD was evaluated over 2 seasons combined (confirmatory secondary objective, success criterion: lower limits of 2-sided CIs around efficacy estimates >20%).
Results
The efficacy analysis comprised 24 967 participants (RSV_1dose: 6227; RSV_revaccination: 6242; placebo: 12 498). Median efficacy follow-up was 17.8 months. Efficacy over 2 seasons of 1 RSVPreF3 OA dose was 67.2% (97.5% CI: 48.2–80.0%) against RSV-LRTD and 78.8% (95% CI: 52.6–92.0%) against severe RSV-LRTD. Efficacy over 2 seasons of a first dose followed by revaccination was 67.1% (97.5% CI: 48.1–80.0%) against RSV-LRTD and 78.8% (95% CI: 52.5–92.0%) against severe RSV-LRTD. Reactogenicity/safety of the revaccination dose were similar to dose 1.
Conclusions
One RSVPreF3 OA dose was efficacious against RSV-LRTD over 2 RSV seasons in ≥60-year-olds. Revaccination 1 year post–dose 1 was well tolerated but did not seem to provide additional efficacy benefit in the overall study population. Clinical Trials Registration ClinicalTrials.gov: NCT04886596.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bethesda, Maryland, USA.
- Pulmonary Division, University of Ferrara, St. Anna University Hospital, Ferrara, Italy.
- Barwon Health, University Hospital Geelong, Geelong, Australia.
- Centre for Innovation in Infectious Diseases and Immunology Research, Deakin University, Geelong, Australia.
- Senior Clinical Trials, Inc, Laguna Hills, California, USA.
- Canadian Center for Vaccinology, Dalhousie University, IWK Health and Nova Scotia Health, Halifax, Canada.
ORCID-Profile: Marie Van der Wielen
Förderung
- GlaxoSmithKline Biologicals SA
Zitieren
APA
Ison, M. G., Papi, A., Athan, E., Feldman, R. G., Langley, J. M., Lee, D. G., Leroux-Roels, I., Martinon-Torres, F., Schwarz, T. F., van Zyl-Smit, R. N., Verheust, C., Dezutter, N., Gruselle, O., Fissette, L., David, M. P., Kostanyan, L., Hulstrøm, V., Olivier, A., Van der Wielen, M., …, & AReSVi-006 Study Group (2024). Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clinical Infectious Diseases, 78(6), 1732-1744. https://doi.org/10.1093/cid/ciae010
Vancouver
Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, et al. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clinical Infectious Diseases. 2024;78(6):1732-1744. doi:10.1093/cid/ciae010
BibTeX
@article{Ison2024,
author = {Ison, Michael G and Papi, Alberto and Athan, Eugene and Feldman, Robert G and Langley, Joanne M and Lee, Dong-Gun and Leroux-Roels, Isabel and Martinon-Torres, Federico and Schwarz, Tino F and van Zyl-Smit, Richard N and Verheust, Céline and Dezutter, Nancy and Gruselle, Olivier and Fissette, Laurence and David, Marie-Pierre and Kostanyan, Lusine and Hulstrøm, Veronica and Olivier, Aurélie and Van der Wielen, Marie and Descamps, Dominique and AReSVi-006 Study Group, AReSVi-006 Study Group},
title = {Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {78},
number = {6},
pages = {1732--1744},
doi = {10.1093/cid/ciae010}
}
EUVIMED